|Bid||2.30 x 4000|
|Ask||2.50 x 800|
|Day's Range||2.35 - 2.42|
|52 Week Range||1.85 - 4.35|
|Beta (3Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
NEW YORK, Nov. 08, 2018 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated.
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers NEW YORK, Oct. 30, 2018 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:.
In fact, there are additional sectors that have just begun to gain investor interest with regard to new advancements in technology. The global big data in the healthcare market is gaining interest and this has been due to the introduction of personalized healthcare systems and demand for high-quality healthcare services. With this technology, healthcare providers are adding to their capabilities by analyzing patient behavior towards a particular treatment and diagnostic patterns, in order to provide them with customized and highly cost-effective services.
Late-Breaking Data Demonstrate Significant Association Between Higher ANAVEX®2-73 Concentration and Maintained Activities of Daily Living and Reduced Cognitive Decline in.
Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers NEW YORK, Oct. 19, 2018 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:.
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Anyone researching Anavex Life Sciences Corp (NASDAQ:AVXL) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and Read More...
NEW YORK, Sept. 26, 2018-- Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases ...
ANAVEX ® 2-73 Being Studied as Potential First Precision Medicine Biomarker-guided, Targeted Therapeutic in Alzheimer’ s Disease Primary and Secondary Endpoints measuring Safety, and Cognitive and Functional ...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Anavex Life Sciences Corp. (NASDAQ: AVXL ) will be discussing their earnings results in their Q3 Earnings Call to be held on August 9, 2018 at 4:30 PM Eastern ...
On a per-share basis, the New York-based company said it had a loss of 6 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
NEW YORK, NY / ACCESSWIRE / July 4, 2018 / Health stocks Anavex Life Sciences Corp. and Juniper Pharmaceuticals were both exploding in Tuesday trading on positive developments. Anavex announced it has ...
Today, Anavex Life Sciences (AVXL) announced approval from the Australian Human Research Ethics Committee to initiate its Phase 2b/3 trial evaluating investigational therapy ANAVEX2-73 in early Alzheimers’ disease. Avanex Life Sciences plans to initiate Phase 2 programs evaluating ANAVEX2-73 in Rett syndrome and Parkinson’s disease indications in H2 2018.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Herman Miller, Inc. (NASDAQ: MLHR ) stock was trading ...
Global fund managers overweight U.S. stocks in June for the first time in 15 months, as profit outlook remains best in the world.